Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesAripiprazole versus other atypical antipsychotics for schizophrenia
Cochrane Reviews, 10/20/09
Komossa K et al. – There were only four studies on two comparisons – aripiprazole compared to olanzapine and aripiprazole compared to risperidone. On the basis of very limited data aripiprazole was not as effective as olanzapine but as good as risperidone. Aripiprazole was associated with less weight gain, cholesterol increase, sedation and prolactin related effects than olanzapine. Compared to risperidone aripiprazole produced fewer dystonias, cardiac arrhythmias, prolactin and cholesterol increase.
Related Articles
Effectiveness of Switching to Aripiprazole From Atypical Antipsychotics in Patients With Schizophrenia
Clinical Neuropharmacology, 10/12/09
Relevance Score: 68%
Beyond symptom dimensions: Schizophrenia risk factors for patient groups derived by latent class analysis
Schizophrenia Research, 10/30/09
Relevance Score: 46%
Functional Magnetic Resonance Imaging of Inner Speech in Schizophrenia
Biological Psychiatry, 10/26/09
Relevance Score: 46%
Age at onset and cognition in schizophrenia: meta-analysis
British Journal of Psychiatry, 10/06/09
Relevance Score: 46%
Auditory gating deficit to human voices in schizophrenia: A MEG study
Schizophrenia Research, 10/01/09
Relevance Score: 46%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effects of Methylphenidate on Cerebral Glucose Metabolism in Patients With Impaired Consciousness After Acquired Brain Injury
Clinical Neuropharmacology, 12/07/09
Gabapentin Enacarbil in Restless Legs Syndrome: A Phase 2b, 2-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Clinical Neuropharmacology, 12/07/09
Bayer HealthCare Pharmaceuticals Inc. Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimer's Disease
Bayer HealthCare Pharmaceuticals, 12/07/09
Sponsor
Article Search
Sponsor